Ref: NEPHROPLUS/SE/82

September 1, 2026

To	To
BSE Limited	**National Stock Exchange of India Limited**
P.J. Towers, Dalal Street,	5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 001	Mumbai – 400 051
Scrip Code: 544647	*Scrip Symbol: NEPHROPLUS*
Through: BSE Listing Centre	*Through: NEAPS*

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Acquisition of 100% participatory interest in "Dialysis Center Almaty" LLP, Kazakhstan

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI Listing Regulations, we hereby inform that NEPHROPLUS HEALTH SERVICES KAZAKHSTAN LLP ("**NPHSK LLP**"), an overseas step-down subsidiary of Nephrocare Health Services Limited ("**Company**"), has, on September 1, 2026, entered into a Sale and Purchase Agreement ("**SPA**") with Ms. Aizhan Slambekovna Zhambulova ("**Seller**") for acquisition of 100% participatory interest in the charter capital of "Dialysis Center Almaty" LLP ("**Target Entity**"), a limited liability partnership incorporated under the laws of the Republic of Kazakhstan.

The aggregate consideration payable for the acquisition is KZT 561.66 million (Kazakhstani Tenge Five Hundred Sixty-One Million Six Hundred Sixty-Three Thousand Five Hundred Ten only) (Approx. ₹116.35 million), subject to such downward adjustments as may be applicable in accordance with the terms of the SPA.

The completion of the acquisition is subject to fulfilment or waiver, as applicable, of the conditions precedent and completion of the closing actions contemplated under the SPA. Upon completion of the transaction, NPHSK LLP will hold 100% participatory interest in the Target Entity, and consequently, the Target Entity will become an overseas step-down subsidiary of the Company.

The acquisition is in line with the Company's strategy of expanding its dialysis services network in international markets and will further strengthen the Company's presence in Kazakhstan.

The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI Master Circular are enclosed as ***Annexure I***.

The aforesaid information is also being made available on the website of the Company www.nephroplus.com.

For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore Digitally signed by Kathri Kishore Date: 2026.09.01 23:44:07 +05'30'

Kishore Kathri
Company Secretary & Head Legal
ICSI M. No. F9895

ANNEXURE I

Sr. No	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.	Dialysis Center Almaty LLP ("**Target Entity**"), a limited liability partnership incorporated under the laws of the Republic of Kazakhstan. The Target Entity is engaged in the business of providing dialysis services through its dialysis centres in Kazakhstan. Last audited turnover of the Target Entity is KZT 527.44 million (approx. ₹10.93 crore).
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	The acquisition does not constitute a related party transaction. The Promoter, Promoter Group and/or Group Companies of the Company do not have any interest in the Target Entity or the Seller.
3.	Industry to which the entity being acquired belongs.	Healthcare – Dialysis services.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	The acquisition is in line with the Company's existing business and its strategy of expanding its dialysis services network in international markets. The acquisition is expected to strengthen the Company's presence and operating platform in Kazakhstan and support the further expansion of its dialysis services business in the region.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	The acquisition and transfer of the participatory interest are subject to completion of the applicable statutory and regulatory formalities under the laws of the Republic of Kazakhstan, including state re-registration of the Target Entity in connection with the transfer of the participatory interest to NPHSK LLP, and such other approvals/registrations, if any, as may be applicable.
6.	Indicative time period for completion of the acquisition.	The acquisition will be completed upon satisfaction or waiver, as applicable, of the conditions precedent and completion of the closing actions contemplated under the SPA.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same.	Cash consideration.

8.	Cost of acquisition and/or the price at which the shares are acquired.	KZT 561.66 million (Kazakhstani Tenge Five Hundred Sixty-One Million Six Hundred Sixty-Three Thousand Five Hundred Ten only) (Approx. ₹116.35 million), subject to downward adjustments, if any, in accordance with the terms of the SPA.
9.	Percentage of shareholding/control acquired and/or number of shares acquired.	100% participatory interest in the charter capital of the Target Entity. Upon completion of the acquisition, NPHSK LLP will hold 100% of the participatory interest in and exercise control over the Target Entity.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last three years' turnover, country in which the acquired entity has presence and any other significant information (in brief).	The Target Entity was incorporated on February 22, 2019 under the laws of the Republic of Kazakhstan and is engaged in providing dialysis services through its dialysis centres. It operates in Kazakhstan and has 34 dialysis machines. Turnover for the last three financial years: Calendar Year 2023: KZT 435.35 million (approx. ₹9.02 crore) Calendar Year 2024: KZT 493.83 million (approx. ₹10.23 crore) Calendar Year 2025: KZT 527.44 million (approx. ₹10.93 crore)

***